Granted Patent
B2
US 12,559,531 · App. 17/712,562 · Granted Feb 24, 2026
Claudin-6-specific immunoreceptors and T cell epitopes
Inventors:
Ugur Sahin (Mainz, DE); Özlem Türeci (Mainz, DE); Petra Simon (Mainz, DE); Tana Omokoko (Mainz, DE); Holger Hoff (Mainz, DE); Ralf-Holger Voss (Ingelheim, DE); Andrea Breitkreuz (Worms, DE); Kathleen Hobohm (Kelkheim i. Ts, DE); Karolina Anna Mroz (Wiesbaden, DE)
Assignees:
BIONTECH CELL & GENE THERAPIES GMBH; TRON-TRANSLATIONALE ONKOLOGIE AN UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GE; ASTELLAS PHARMA INC.
C07K14/4748A61K40/11A61K40/31A61K40/32A61K40/4202A61K40/428C07K14/7051C07K14/70521C07K14/70539C07K16/28G01N33/505G01N33/56972G01N33/574A61K38/00A61K2239/31A61K2239/38A61K2239/59C07K2317/56C07K2317/622C07K2319/02C07K2319/03C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides Claudin-6-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.
Claims (11)
1 . An artificial T cell receptor comprising:
a binding domain for claudin-6 (CLDN6) comprising the amino acid sequence of SEQ ID NO: 40;
a costimulatory domain selected from the group consisting of: CD28, CD137 (4-1BB), CD134 (OX40), and CD278 (COS); and
a T cell signaling domain that activates cytotoxic lymphocytes upon binding to CLDN6.
2 . The artificial T cell receptor of claim 1 , wherein the costimulatory domain is CD137 (4-1BB).
3 . The artificial T cell receptor of claim 1 , further comprising a transmembrane domain.
4 . The artificial T cell receptor of claim 3 , further comprising a spacer region which links the binding domain for CLDN6 to the transmembrane domain.
5 . The artificial T cell receptor of claim 1 , wherein the T cell signaling domain comprises the endodomain of CD3-zeta or a functional fragment thereof.
6 . The artificial T cell receptor of claim 1 which comprises a signal peptide which directs the nascent protein into the endoplasmic reticulum.
7 . The artificial T cell receptor of claim 6 , which comprises the structure:
NH2-signal peptide-binding domain for CLDN6-spacer region-transmembrane domain-T cell signaling domain-COOH.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 19, 2024
From: SAHIN, UGUR; TÜRECI, ÖZLEM; SIMON, PETRA; OMOKOKO, TANA; HOFF, HOLGER; VOSS, RALF-HOLGER; BREITKREUZ, ANDREA; HOBOHM, KATHLEEN; MROZ, KAROLINA ANNA
To: BIONTECH CELL & GENE THERAPIES GMBH; TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNUTZIGE GMBH; UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ; GANYMED PHARMACEUTICALS AG
Reel/Frame 068635/0173 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 19, 2024
From: UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ
To: TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNUTZIGE GMBH
Reel/Frame 068635/0418 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 3, 2024
From: GANYMED PHARMACEUTICALS GMBH
To: ASTELLAS PHARMA INC.
Reel/Frame 066010/0062 →
Continuity (3)
Division
15124640
References Cited (42)
US 20130282285A1
· Boquet et al.
· 2013
[cited by applicant]
CN 101316610A
· 2008
[cited by applicant]
CN 102325885A
· 2012
[cited by applicant]
EP 2103628A1
· 2009
[cited by applicant]
EP 2138576A1
· 2009
[cited by applicant]
EP 2322555A1
· 2011
[cited by applicant]
KR 20140005837A
· 2014
[cited by applicant]
WO 2008114733A1
· 2008
[cited by applicant]
WO 2010094499A1
· 2010
[cited by applicant]
WO 2011057788A1
· 2011
[cited by applicant]
WO 2011113546A1
· 2011
[cited by applicant]
WO 2011130346A1
· 2011
[cited by applicant]
WO 2012156018A1
· 2012
[cited by applicant]
WO WO2012156018
· 2012
[cited by examiner]
WO 2013126712A1
· 2013
[cited by applicant]
Chekmasova AA, Brentjens RJ. Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancer. Discov Med. Jan. 2010;9(44):62-70.
[cited by applicant]
English et al., Claudins overexpression in ovarian cancer: potential targets for Clostridium Perfringens Enterotoxin (CPE) based diagnosis and therapy. Int J Mol Sci. May 17, 2013;14(5):10412-10437.
[cited by applicant]
Notice of Opposition in corresponding European Patent Application No. 15712657.4 issued on Oct. 22, 2019. 29 pages.
[cited by applicant]
No Author. UniProtKB. P56747 (CLDN_Human). Mar. 7, 2006. 10 pages.
[cited by applicant]
No Author. European Nucleotide Archive. Sequence: AY35840.1. Oct. 9, 2003. 2 pages.
[cited by applicant]
Meertens et al. “The Tight Junction Proteins Claudin-1,-6, and-9 are Entry Cofactors for Hepatitis C Virus.” Journal of Virology 82.7 (2008): 3555-3560.
[cited by applicant]
Vonderheide et al. “Engineering T cells for cancer: our synthetic future.” Immunological Reviews 257.1 (2014). 10 pages.
[cited by applicant]
Indian Examination Report for corresponding Indian Patent Application No. 201647033069 dated Jan. 24, 2020. 6 pages.
[cited by applicant]
Morita Kazumasa et al: “Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands.” Proceedings of the National Academy of Sciences, National Academy of Sciences, vol. 96, …
[cited by applicant]
Sonja Offner et al: “Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapy.” Cancer Immunology, Immunotherapy, vol. 54, No. 5, May 1, 2005, pp. 431-445.
[cited by applicant]
M Lal-Nag et al: “Claudin-6: a novel receptor for CPE-mediated cytotoxicity in ovarian cancer.” Oncogenesis, vol. I, No. 11, Nov. 1, 2012, p. e33.
[cited by applicant]
J. S. Mattsson et al: “Abstract A37: Ectopic claudin 6 and 18.2 expression as potential treatment target in non-small cell lung cancer.” Clinical Cancer Research, vol. 20, No. 2 Supplement, Jan. 15, 2014, pp. A37-A37.
[cited by applicant]
International Search Report and Written Opinion in corresponding PCT Application No. PCT/EP2015/056899 dated Jun. 10, 2015.
[cited by applicant]
International Preliminary Report on Patentability corresponding PCT Application No. PCT/EP2015/056899 dated Oct. 13, 2016.
[cited by applicant]
Lal-Nag et al. “The claudins”, Genome Biology, 2009, 10:235.
[cited by applicant]
Pinthus et al. “Immuno-Gene Therapy of Established Prostate Tumors Using Chimeric Receptor-redirected Human Lymphocytes.” May 15, 2003, Cancer Research, 63: 2470-2476.
[cited by applicant]
Beyer et al. “Overcoming Physical Barriers in Cancer Therapy.” Jan./Feb./Mar. 2013, Tissue Barriers 1:1 e23647.
[cited by applicant]
Furuse et al. “A single Gene Product, Claudin-1 or -2, Reconstitutes Tight Junction Strands and Recruits Occludin In Fibroblasts.” Oct. 19, 1998, J. Cell Biol. 143(2): 391-401.
[cited by applicant]
Klein et al. “Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10.” May 5, 2009, PNAS 106(18): 7385-7390.
[cited by applicant]
Strokotov et al. “Is there a difference between T- and B-lymphocyte morphology.” Nov./Dec. 2009, J. biomed optics 14(6):064036.
[cited by applicant]
Tsukita et al. “Multifunctional Strands in Tight Junctions.” Apr. 2001, Nature Reviews. Mol cell biol. 2:285-293.
[cited by applicant]
Lamers et al. “Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of pat…
[cited by applicant]
Jena et al. “Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.” Blood 116.7 (2010): 1035-1044.
[cited by applicant]
Lamers et al. “Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.” Molecular therapy 21.4 (2013): 904-912.
[cited by applicant]